M 3000

Drug Profile

M 3000

Alternative Names: M-3000

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SyndromeX
  • Class Anti-inflammatories; Antineoplastics
  • Mechanism of Action AMP activated protein kinase modulators; FOXO1 protein expression modulators; Hepatocyte nuclear factor 4 modulators; Mitochondrial permeability transition pore modulators; STAT3 transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation
  • Research Cancer

Most Recent Events

  • 25 Jul 2016 Early research in Cancer in Israel (PO)
  • 25 Jul 2016 Preclinical trials in Autoimmune disorders in Israel (PO)
  • 25 Jul 2016 Preclinical trials in Inflammation in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top